Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.55 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7651672 | 0.98 | HRH3 (0.63) | HRH3CYP1A2HSD17B10HRH4PLD1 | |
| Hydrochloric Acid SCHEMBL6977782 | 0.98 | HRH3 (0.63) | HRH3CYP1A2HSD17B10HRH4PLD1 | |
| SCHEMBL6977620 | 0.84 | HRH3 (0.48) | HRH3CYP1A2HSD17B10HRH4ALDH1A1 | |
| SCHEMBL24799135 | 0.83 | SORD (0.48) | HRH3CYP1A2HSD17B10HRH4ALDH1A1 | |
| SCHEMBL3167113 | 0.83 | CXCR4 (0.49) | HRH3HRH4KDM4EUSP2SORD | |
| SCHEMBL13750595 | 0.81 | CXCR4 (0.51) | HRH3HRH4KDM4EUSP2TDP1 | |
| SCHEMBL31553317 | 0.81 | CXCR4 (0.51) | HRH3HRH4KDM4EUSP2TDP1 | |
| Hydrochloric Acid SCHEMBL7654208 | 0.81 | HRH4 (0.49) | HRH3CYP1A2HSD17B10HRH4SORD | |
| SCHEMBL206002 | 0.80 | SORD (0.46) | HRH3CYP1A2HSD17B10HRH4ALDH1A1 | |
| SCHEMBL5112284 | 0.80 | SORD (0.46) | HRH3CYP1A2HSD17B10HRH4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9944666-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944666-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-0925286-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| US-6093718-A | AN OXIDO-SQUALENE CYCLASE INHIBITOR, ANTICHOLESTEROL AGENT FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND LOWERING CHOLESTEROL LEVELS IN BLOOD PLASMA; TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| CN-1228087-A | Substituted pyrimidine derivatives and their pharmaceutical use | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| EP-0384370-B1 | Substituted pyrimidine derivatives, process for their preparation, and their use as tool | HOECHST AG (DE) | 1993-11-03 | — | — | EP | disclosed |
| US-5138058-A | Diabetic screening | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| EP-0384370-A1 | Substituted pyrimidine derivatives, process for their preparation, and their use as tool | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HRH3 2897/4885CYP1A2 3953/4885HSD17B10 3309/4885 |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | HRH3 534/4885CYP1A2 4209/4885HSD17B10 3792/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH3 2288/4885CYP1A2 3492/4885HSD17B10 2085/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HRH3 3558/4885CYP1A2 3732/4885HSD17B10 3173/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HRH3 3558/4885CYP1A2 3732/4885HSD17B10 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.